• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝门部胆管癌根治术后患者总生存期的预后因素的荟萃分析。

Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma.

机构信息

Northwest Hepatobiliary Centre, University Hospital Aintree, Liverpool, UK.

Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, UK.

出版信息

Br J Surg. 2018 Oct;105(11):1408-1416. doi: 10.1002/bjs.10921. Epub 2018 Jul 12.

DOI:10.1002/bjs.10921
PMID:29999515
Abstract

BACKGROUND

Hilar cholangiocarcinoma is staged using the AJCC staging system. Numerous other prognostically important histopathological and demographic characteristics have been reported. The objective of this meta-analysis was to assess statistically the effect of postresectional tumour characteristics on overall survival of patients undergoing attempted radical curative resection for hilar cholangiocarcinoma.

METHODS

Relevant studies were identified by searching the Ovid MEDLINE and PubMed databases. The search was limited to studies published between 2009 and 2017. Papers referring to intrahepatic or distal cholangiocarcinoma were excluded from review. Data extraction used standard Parmar modifications to determine pooled univariable hazard ratios (HRs).

RESULTS

Twenty-four articles, containing 4599 patients, were assessed quantitatively. In pooled analyses, age (HR 1·16, 95 per cent c.i. 1·04 to 1·28), T category (HR 1·49, 1·30 to 1·70), lymph node involvement (HR 1·78, 1·65 to 1·93), microvascular invasion (HR 1·49, 1·34 to 1·68), perineural invasion (HR 1·54, 1·40 to 1·68) and tumour differentiation (HR 1·54, 1·38 to 1·72) were significant prognostic factors, with low heterogeneity. Portal vein resection (HR 1·54, 1·15 to 1·70) and resection margin status (HR 1·77, 1·57 to 1·99) had significant effects, but with high heterogeneity. Sex, tumour size and preoperative carbohydrate antigen 19-9 levels did not have a statistically significant effect on postoperative prognosis.

CONCLUSION

Several tumour biological variables not included in the seventh edition of the AJCC classification affect overall survival. These require incorporation into prognostic models to ensure a personalized approach to prognostication and treatment.

摘要

背景

肝门部胆管癌采用 AJCC 分期系统进行分期。已经报道了许多其他具有重要预后意义的组织病理学和人口统计学特征。本荟萃分析的目的是评估术后肿瘤特征对接受根治性切除术的肝门部胆管癌患者总体生存的统计学影响。

方法

通过检索 Ovid MEDLINE 和 PubMed 数据库来确定相关研究。搜索范围限于 2009 年至 2017 年发表的研究。从综述中排除了涉及肝内或远端胆管癌的论文。使用 Parmar 标准修改版提取数据,以确定汇总的单变量风险比(HR)。

结果

共评估了 24 篇文章,包含 4599 例患者。在汇总分析中,年龄(HR 1.16,95%可信区间 1.04 至 1.28)、T 分期(HR 1.49,1.30 至 1.70)、淋巴结受累(HR 1.78,1.65 至 1.93)、微血管侵犯(HR 1.49,1.34 至 1.68)、神经周围侵犯(HR 1.54,1.40 至 1.68)和肿瘤分化(HR 1.54,1.38 至 1.72)是显著的预后因素,异质性低。门静脉切除术(HR 1.54,1.15 至 1.70)和切缘状态(HR 1.77,1.57 至 1.99)有显著影响,但异质性高。性别、肿瘤大小和术前癌抗原 19-9 水平对术后预后无统计学影响。

结论

AJCC 分期第七版未包含的几种肿瘤生物学变量影响总体生存。这些因素需要纳入预后模型,以确保采用个体化方法进行预后和治疗。

相似文献

1
Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma.肝门部胆管癌根治术后患者总生存期的预后因素的荟萃分析。
Br J Surg. 2018 Oct;105(11):1408-1416. doi: 10.1002/bjs.10921. Epub 2018 Jul 12.
2
Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases.肝门部胆管癌门静脉切除肝切除术:52例连续病例分析
Ann Surg. 2003 Nov;238(5):720-7. doi: 10.1097/01.sla.0000094437.68038.a3.
3
Intrahepatic, peri-hilar and distal cholangiocarcinoma: Three different locations of the same tumor or three different tumors?肝内、肝门周围及肝外胆管癌:同一肿瘤的三个不同部位还是三种不同肿瘤?
Eur J Surg Oncol. 2015 Sep;41(9):1162-9. doi: 10.1016/j.ejso.2015.05.013. Epub 2015 Jun 10.
4
Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.新时代肝门部胆管癌的外科治疗: 来自首尔峨山医院的经验。
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):476-89. doi: 10.1007/s00534-009-0204-5. Epub 2009 Oct 23.
5
[Diagnostic procedures and results in surgical therapy for cholangiocarcinoma].[胆管癌外科治疗的诊断程序与结果]
Zentralbl Chir. 2014 Dec;139 Suppl 2:e25-34. doi: 10.1055/s-0031-1283831. Epub 2012 Jan 24.
6
Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma.肝门整块切除术治疗肝门部胆管癌的肿瘤学优势。
Ann Surg Oncol. 2012 May;19(5):1602-8. doi: 10.1245/s10434-011-2077-5. Epub 2011 Oct 1.
7
Surgical treatment and prognostic analysis of 93 cases of hilar cholangiocarcinoma.93 例肝门部胆管癌的外科治疗及预后分析。
Am J Med Sci. 2010 Mar;339(3):221-4. doi: 10.1097/MAJ.0b013e3181c7c8b4.
8
Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV.肝门部胆管癌 Bismuth Ⅲ型和Ⅳ型行肝尾叶全切除可带来生存获益。
Eur J Surg Oncol. 2012 Dec;38(12):1197-203. doi: 10.1016/j.ejso.2012.08.009. Epub 2012 Sep 16.
9
Correlation of staging systems to survival in patients with resected hilar cholangiocarcinoma.肝门部胆管癌切除术后患者的分期系统与生存的相关性。
Am J Surg. 2013 Aug;206(2):159-65. doi: 10.1016/j.amjsurg.2012.11.020. Epub 2013 Jun 6.
10
Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre.单中心230例肝门部胆管癌切除手术的结果
ANZ J Surg. 2013 Apr;83(4):268-74. doi: 10.1111/j.1445-2197.2012.06195.x. Epub 2012 Sep 3.

引用本文的文献

1
Treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: a comprehensive review.原发性硬化性胆管炎患者胆管癌的治疗:综述
eGastroenterology. 2024 Mar 29;2(1):e100045. doi: 10.1136/egastro-2023-100045. eCollection 2024 Jan.
2
Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring.胆管癌合并胆道梗阻:用于诊断和早期复发监测的外泌体环状RNA特征
Signal Transduct Target Ther. 2024 May 3;9(1):107. doi: 10.1038/s41392-024-01814-3.
3
National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma.
国家肝门部胆管癌诊断和治疗指南。
World J Gastroenterol. 2024 Mar 7;30(9):1018-1042. doi: 10.3748/wjg.v30.i9.1018.
4
Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma.社论:胆管癌和肝细胞癌的新型治疗方法
Front Cell Dev Biol. 2023 Nov 3;11:1320084. doi: 10.3389/fcell.2023.1320084. eCollection 2023.
5
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.英国胃肠病学会胆管癌诊断和管理指南。
Gut. 2023 Dec 7;73(1):16-46. doi: 10.1136/gutjnl-2023-330029.
6
Preoperative immunological plasma markers TRAIL, CSF1 and TIE2 predict survival after resection for biliary tract cancer.术前免疫血浆标志物TRAIL、CSF1和TIE2可预测胆管癌切除术后的生存率。
Front Oncol. 2023 Jun 19;13:1169537. doi: 10.3389/fonc.2023.1169537. eCollection 2023.
7
Cancer-specific survival in patients with cholangiocarcinoma after radical surgery: a Novel, dynamic nomogram based on clinicopathological features and serum markers.根治性手术后胆管癌患者的癌症特异性生存:一种基于临床病理特征和血清标志物的新型动态列线图。
BMC Cancer. 2023 Jun 12;23(1):533. doi: 10.1186/s12885-023-11040-9.
8
Prognostic impact of preoperative skeletal muscle change from diagnosis to surgery in patients with perihilar cholangiocarcinoma.肝门部胆管癌患者从诊断到手术期间术前骨骼肌变化的预后影响
Ann Gastroenterol Surg. 2022 Dec 11;7(3):523-532. doi: 10.1002/ags3.12644. eCollection 2023 May.
9
The impact of C-reactive protein-albumin-lymphocyte (CALLY) index on the prognosis of patients with distal cholangiocarcinoma following pancreaticoduodenectomy.C反应蛋白-白蛋白-淋巴细胞(CALLY)指数对胰十二指肠切除术后远端胆管癌患者预后的影响
Ann Gastroenterol Surg. 2022 Nov 18;7(3):503-511. doi: 10.1002/ags3.12637. eCollection 2023 May.
10
Survival analysis of extrahepatic cholangiocarcinoma based on surveillance, epidemiology, and end results database.基于监测、流行病学和最终结果数据库的肝外胆管癌生存分析
Ann Hepatobiliary Pancreat Surg. 2023 May 31;27(2):151-157. doi: 10.14701/ahbps.22-090. Epub 2023 Jan 2.